Source:http://linkedlifedata.com/resource/pubmed/id/10656788
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2000-3-7
|
pubmed:abstractText |
The integration of proviral DNA into the genome of the host cell is an essential step in the replication of retroviruses. This reaction is catalyzed by a viral-encoded enzyme, the integrase (IN). We have previously shown that human immunodeficiency virus type 1 (HIV-1) IN causes a lethal effect when expressed in yeast cells. This system, called yeast lethal assay, was used as a tool to study IN activity in a cellular context. The yeast lethal assay allowed the selection and characterization of mutations affecting both the lethal phenotype and the in vitro IN activities. IN mutants were produced by random PCR mutagenesis in an IN gene bearing the inactivating D116A mutation in the catalytic site. The corresponding D116A substituted IN does not lead to lethality in yeast. Subsequent selection of mutants able to restore the lethal effect of IN was carried out using the yeast lethal assay. We isolated three mutants presenting a restored phenotype. The mutated IN genes were sequenced and the corresponding proteins were purified to characterize their in vitro activities. The three mutants presented restoration of the in vitro strand transfer activity, while 3' processing was only partially restored.The three mutants differ from D116A IN by at least one amino acid substitution located in the N-terminal domain of the protein, outside of the active site. These new mutated HIV-1 INs may therefore allow a better understanding of the N-terminal domain function in the integration reaction. In addition, these results support our hypothesis that explains the lethal effect as a consequence of the nuclear damage caused by wild-type IN in yeast cells. These data also indicate that the yeast lethal assay can be used as a tool to study the retroviral integration mechanism in a cellular context and to select specific inhibitors.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0022-2836
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2000 Academic Press.
|
pubmed:issnType |
Print
|
pubmed:day |
28
|
pubmed:volume |
295
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
755-65
|
pubmed:dateRevised |
2009-11-3
|
pubmed:meshHeading |
pubmed-meshheading:10656788-Amino Acid Substitution,
pubmed-meshheading:10656788-Catalytic Domain,
pubmed-meshheading:10656788-Cloning, Molecular,
pubmed-meshheading:10656788-DNA Primers,
pubmed-meshheading:10656788-Endodeoxyribonucleases,
pubmed-meshheading:10656788-HIV Integrase,
pubmed-meshheading:10656788-HIV-1,
pubmed-meshheading:10656788-Humans,
pubmed-meshheading:10656788-Mutagenesis, Site-Directed,
pubmed-meshheading:10656788-Recombinant Proteins,
pubmed-meshheading:10656788-Saccharomyces cerevisiae
|
pubmed:year |
2000
|
pubmed:articleTitle |
Selection of amino acid substitutions restoring activity of HIV-1 integrase mutated in its catalytic site using the yeast Saccharomyces cerevisiae.
|
pubmed:affiliation |
Laboratoire REGER, UMR 5097 CNRS-Université Victor Segalen Bordeaux 2, IFR 66 Pathologies Infectieuses. 1, rue Camille Saint Saëns, Bordeaux cedex, 33077, France. vincent.parissi@ibgc.u-bordeaux2.fr
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|